At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/dermatomyositis-targeted-drug-shows-promise-vs-placebo-2026a10009iz?src=rss
Author :
Publish date : 2026-03-29 16:39:00
Copyright for syndicated content belongs to the linked Source.
